Fostamatinib Disodium Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 150 mg
Reference Brands: Tavalisse (USA)
Category:
Immune Disorder
Fostamatinib disodium is available in Tablets
and strengths such as 100 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fostamatinib disodium is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fostamatinib disodium can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fostamatinib is an orally available immunomodulating and anti-inflammatory medicine used primarily in the treatment of certain immune-mediated disorders. It is formulated as a disodium salt and acts as a spleen tyrosine kinase (Syk) inhibitor. By selectively blocking Syk kinase activity, fostamatinib interferes with IgG Fc gamma receptor signaling pathways that are involved in immune cell activation. This leads to reduced activation of mast cells, macrophages, and B-cells, thereby decreasing inflammatory responses and immune-related tissue damage.
Syk kinase is widely expressed in hematopoietic cells and plays an important role in transmitting signals from activated immunoreceptors to downstream cellular processes such as proliferation, differentiation, and phagocytosis. By interrupting these signaling pathways, fostamatinib helps control abnormal immune activation. Clinically, fostamatinib is used for the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous therapies. Its targeted mechanism makes it a valuable option in conditions driven by antibody-mediated immune activity, offering a focused approach to immune regulation.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing